I always appreciate the copy of that data to look over as I find it interesting the mechanism of the life-cycle and in turn the inhibitors ability to interupt such.
I guess it is just my inquisitve nature, as I have worked in data research for the better part of 35 years.(not HCV).
This particular pooled -data is "current" and " Not" a small number of patients .(approx.1300)
I found it very interesting that it states that all the relaspers were indeed UND. @week4 and that many of the ones that went on to SVR were UND. much later
Granted this is study was done on Mavyret only.
As seen ,the time to viral suppression was looked at by a number of factors(ie. GT, BMI, PPI use, Fibrosis Stage and RAS).
So ,it would seem (to me anyway) that they are looking at more specific reasons and what factors go into the speed of decline and what at the end of the day that means in terms of SVR, rather than just a broad based approch of "extend if there is late decline"
Again thanks,appreciate it.
Diagnosed: 2001 GT1a , HCV since mid-70's.
Biopsy 2010 F1
Fibroscan and Fibrosure 2018 F2
Treated in trial 2010 with Dac/Peg/ Riba and Relapsed.
Resistance test 2017. Have Ns5a Rav Q30r/H58d enhanced from doing Dac.
Start Tx. Jan 18th/18 w/ Vosevi /Riba 12wks. plus 6 wks.Viekira Pak +Sof/Riba(From Dr Freeman @GP2U)
VL start: 1.6mill.ALT 125 AST 88
Wk. 4 Det @LLOQ <15.
VL Wk.8 UND Alt &Ast 22
Wk. 12 UND
EOT+12 >>>UND (SVR12)! ALT11 AST13
Nov6/18 SVR 24!